Potential Role for Statins in the Treatment of Chronic HCV Infection
Qianqian Zhu,Qunying Han,Zhengwen Liu
DOI: https://doi.org/10.2217/fvl.13.70
2013-01-01
Future Virology
Abstract:Future VirologyVol. 8, No. 8 EditorialFree AccessPotential role for statins in the treatment of chronic HCV infectionQianqian Zhu, Qunying Han & Zhengwen LiuQianqian ZhuDepartment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, No. 277 Yanta West Road, Xi’an, 710061, Shaanxi Province, ChinaSearch for more papers by this author, Qunying HanDepartment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, No. 277 Yanta West Road, Xi’an, 710061, Shaanxi Province, ChinaSearch for more papers by this author & Zhengwen Liu* Author for correspondenceDepartment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, No. 277 Yanta West Road, Xi’an, 710061, Shaanxi Province, China. .Search for more papers by this authorEmail the corresponding author at liuzhengwen@medmail.com.cnPublished Online:5 Aug 2013https://doi.org/10.2217/fvl.13.70AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail Keywords: chronic hepatitis Cdirect-acting antiviralhost-targeting agentIFN-αribavirinstatintreatmentInfection with HCV is a major cause of chronic liver disease and hepatocellular carcinoma (HCC). The standard of care (SOC) for HCV genotype 1 is now pegylated IFN-α (PEG-IFN-α), ribavirin (RBV) and a direct-acting antiviral (DAA; also known as a protease inhibitor [PI]) triple therapy, and the PEG-IFN-α and RBV dual therapy remains the SOC for HCV genotypes 2 and 3. The triple therapy containing a DAA such as boceprevir or telaprevir has a sustained virologic response (SVR) rate of approximately 70% among treatment-naive patients with HCV genotype 1 [1,2], and the SVR rate for genotypes 2 and 3 with dual therapy is approximately 80%. There remains room for improvement in the therapy of chronic HCV infection. Furthermore, selection for drug-resistant variants [3], higher rate of adverse events (AEs), increased withdrawals [2] and the high costs associated with the addition of DAAs, as well as the unavailability of DAAs in some countries and areas, limit the general use of DAAs. Therefore, the discovery of novel regimens with the potential to surmount the drawbacks of the current SOCs is a matter of urgency for chronic HCV infection.Given the intimate connection between the HCV life cycle and the lipid metabolism pathway, statins, a class of agents used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, were hypothesized to interfere with HCV viral replication [4,5]. In in vitro studies, statins were suggested to inhibit HCV replication by interfering with the synthesis of cholesterol, which is essential for the synthesis of lipoviroparticles (the infectious HCV particles), and by disturbing the formation of geranylgeranylated proteins, including the geranylgeranylated FBL2, which was identified to promote HCV replication through direct binding to NS5A [6,7]. Furthermore, the combination of some statins, such as fluvastatin and IFN-α, was demonstrated to display strong synergistic inhibitory effects on HCV replication [4]. Statins were also shown to increase the in vitro antiviral activity of different DAAs and delay or prevent the development of resistance to DAAs [5].Clinically, the effect of statins on HCV replication in human subjects has been investigated. Statins used as monotherapy in patients with chronic HCV infection showed contrasting results [8–10]. However, increasing data have shown that statins, when added to IFN-α/PEG-IFN-α and RBV, significantly increase the SVR rate in patients with chronic HCV infection, including those with genotype 1 infection [11–14]. This beneficial effect of statins on chronic HCV infection has been confirmed by a recent meta-analysis based on randomized controlled trials [15].So far, the therapeutic effect of statins on chronic HCV infection has been mainly demonstrated in combination with IFN-α/PEG-IFN-α and RBV for different HCV genotypes, particularly genotype 1. With the continuing advent of novel agents, including DAAs and host-targeting agents (host cofactor inhibitors), statins may play an evolving role in the treatment of chronic HCV infection.Currently, because the triple therapy with PEG-IFN-α, RBV and a DAA is the SOC for HCV genotype 1 and the dual therapy with PEG-IFN-α and RBV is the SOC for the other HCV genotypes, statin applications could include, but may not be limited to, the following conditions: first, statins may be used in patients who have HCV genotype 1 infection but are contraindicated, not indicated or intolerable to DAAs. Second, for patients with HCV genotype 1 infection in the countries or areas where DAAs have not been approved for the treatment of HCV infection, statins may be added to the dual therapy to increase the SVR rate. Third, statins may be administered with compatible DAAs, such as boceprevir, in the triple therapy to further increase the SVR rate in HCV genotype 1 patients [1]. Fourth, statins may be added to the PEG-IFN-α and RBV dual therapy to reduce relapses after discontinuation of treatment [16] and to decrease the incidence of HCC associated with HCV infection [17]. Finally, statins may play a role in the individualized treatment of chronic HCV patients with comorbidities such as diabetes to improve the SVR rate [18].Potentially, statins may play a role in several aspects of treating chronic HCV infection. IFN-free regimens represent an important current and future focus in the treatment of HCV infection and are being investigated in clinical trials with encouraging results. For example, the combination of different DAAs or DAAs with RBV was indicated to achieve SVR in some patients [19]. Statins have been demonstrated to have additive inhibitory effects to DAAs on HCV replication [5] and to delay or prevent the development of resistance to DAAs in vitro[5]. Host-targeting agents have a high barrier to viral resistance and may offer broad coverage of different genotypes. Theoretically, the combination of DAAs and host-targeting agents such as statins may have the advantages of synergistic antiviral effects, low rates of resistance development and broad coverage of viral genotypes. Inhibiting virus infection at multiple steps of the virus life cycle may enable more potent antiviral activity and a reduced chance of resistance development. Therefore, statins combined with compatible DAAs, including PIs and other host-targeting agents, such as cyclophilin A inhibitors, may constitute efficient all-oral IFN/RBV-free regimens targeting multiple stages in viral replication with pan-genotypic coverage of HCV in the future. Statins are potentially useful for preventing the development of HCV resistance or for rescue therapy if resistance develops against future DAAs therapies. The addition of statins to antiviral therapy may also reduce the treatment duration based on response-guided therapy for chronic HCV infection.Certainly, many issues remain to be addressed regarding statins in the treatment of HCV infection. For example, although the addition of statins to IFN-α/PEG-IFN-α and RBV significantly increases SVR rates in all patients and in genotype 1 patients [15], no large-scale randomized controlled trials regarding patients with genotypes other than genotype 1 have been conducted. Therefore, the potential effects of statins on HCV genotypes other than genotype 1 require further evaluation. Different statins with various doses have been used in the studies reported to date. The potency of the in vitro anti-HCV activity of different statins is not the same. Moreover, the same statin, such as fluvastatin and simvastatin, displayed inconsistent potency in terms of in vitro anti-HCV activity in different studies, possibly because of the use of different evaluation methods [4,5]. Fluvastatin appears to be used more frequently and is one of the best-characterized statins, with few drug–drug interactions [20]. The safety and efficacy of fluvastatin combined with IFN-α/PEG-IFN-α and RBV for the treatment of chronic HCV infection have also been confirmed. However, further studies aiming to discriminate the statins with optimal anti-HCV activity in order to optimize the doses of statins used and to characterize the drug–drug interactions between statins and coadministered drugs are also needed. The so-called ‘difficult-to-cure’ patients, such as nonresponders and relapsers, are a major focus in the treatment of HCV infection. The increase of SVR owing to the addition of statins to treatment highlights the positive contribution of statins to at least a subgroup of these patients. Whether the patients in this subgroup who benefit from the addition of statins to different regimens of therapy are identifiable is also an interesting and elusive issue that needs to be addressed. The role of statins in special patient populations, such as those with HCV/HIV coinfections and those with HCV-associated cirrhosis or HCC, also needs to be clarified.Finally, although statins, either alone or in combination with IFN-α/PEG-IFN-α and RBV, have thus far been shown to be safe in chronic HCV patients, the safety concerns possibly connected with the use of statins cannot be ignored. The pharmacokinetic profile of statins related to drug–drug interaction may affect the occurrence of AEs through CYP3A and/or OATP1B1. The concentration of statins may be influenced when coadministered with HCV PIs through CYP3A or OATP1B1 [20]. Both the current statin-containing triple therapy and the future statin-formulating regimens, especially those with DAAs (i.e., PIs), require a more comprehensive understanding of potential drug–drug interactions. Therefore, caution should be taken before statins are widely recommended as an ingredient of treatment regimens, and close monitoring at regular time intervals regarding AEs and the changes of relevant parameters, such as cholesterol levels, biochemical liver function and creatine kinase concentration, is needed if a statin-containing therapy is administered.Overall, statins expand the options for the management of HCV. Similar to other host cofactor inhibitors, statins may become essential components of combination therapy, particularly for patients who are infected with HCV genotype 1, for whom it would be inappropriate to use DAAs and who have difficult-to-cure HCV infection with the current SOCs. They may also become essential in the design of future all-oral IFN-α/RBV-free regimens. Devising optimal statin-containing combination regimens with potent antiviral activity, little or no cross-resistance, few AEs, few drug–drug interactions and pan-genotypic coverage of HCV is theoretically rational and practically feasible and thus may become one of the future focuses in curing HCV infection.Financial & competing interests disclosureThe authors’ research is supported by a grant from the National Natural Science Foundation of China (grant no. 81071371). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.References1 Poordad F, McCone J Jr, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med.364(13),1195–1206 (2011).Crossref, Medline, CAS, Google Scholar2 Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med.364(25),2405–2416 (2011).Crossref, Medline, CAS, Google Scholar3 Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J. Hepatol.55(1),192–206 (2011).Crossref, Medline, CAS, Google Scholar4 Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology44(1),117–125 (2006).Crossref, Medline, CAS, Google Scholar5 Delang L, Paeshuyse J, Vliegen I et al. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology50(1),6–16 (2009).Crossref, Medline, CAS, Google Scholar6 Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc. Natl Acad. Sci. USA102(7),2561–2566 (2005).Crossref, Medline, CAS, Google Scholar7 Wang C, Gale M Jr, Keller BC et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol. Cell18(4),425–434 (2005).Crossref, Medline, CAS, Google Scholar8 O’Leary JG, Chan JL, McMahon CM, Chung RT. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology45(4),895–898 (2007).Crossref, Medline, Google Scholar9 Bader T, Fazili J, Madhoun M et al. Fluvastatin inhibits hepatitis C replication in humans. Am. J. Gastroenterol.103(6),1383–1389 (2008).Crossref, Medline, CAS, Google Scholar10 Patel K, Jhaveri R, George J et al. Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C. J. Viral Hepat.18(5),331–337 (2011).Crossref, Medline, CAS, Google Scholar11 Sezaki H, Suzuki F, Akuta N et al. An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. Intervirology52(1),43–48 (2009).Crossref, Medline, CAS, Google Scholar12 Malaguarnera M, Vacante M, Russo C et al. Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with α-interferon and ribavirin: rosuvastatin reduces NAFLD in HCV patients. Hepat. Mon.11(2),92–98 (2011).Crossref, Medline, Google Scholar13 Shimada M, Yoshida S, Masuzaki R, Schuppan D. Pitavastatin enhances antiviral efficacy of standard pegylated interferon plus ribavirin in patients with chronic hepatitis C: a prospective randomized pilot study. J. Hepatol.56(1),299–300 (2012).Crossref, Medline, Google Scholar14 Kondo C, Atsukawa M, Tsubota A et al. An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin. J. Viral Hepat.19(9),615–622 (2012).Crossref, Medline, CAS, Google Scholar15 Zhu Q, Li N, Han Q et al. Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: a systematic review and meta-analysis. Antiviral Res.98(3),373–379 (2013).Crossref, Medline, CAS, Google Scholar16 Atsukawa M, Tsubota A, Kondo C et al. Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b. J. Gastroenterol. Hepatol.28(1),51–56 (2013).Crossref, Medline, CAS, Google Scholar17 Tsan YT, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J. Clin. Oncol.31(12),1514–1521 (2013).Crossref, Medline, Google Scholar18 Rao GA, Pandya PK. Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C. Gastroenterology140(1),144–152 (2011).Crossref, Medline, CAS, Google Scholar19 Gane EJ, Stedman CA, Hyland RH et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med.368(1),34–44 (2013).Crossref, Medline, CAS, Google Scholar20 Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drug–drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin. Pharmacokinet. doi:10.1007/s40262-013-0075-4 (2013) (Epub ahead of print).Medline, Google ScholarFiguresReferencesRelatedDetailsCited ByPlausible Positive Effects of Statins in COVID-19 Patient13 July 2021 | Cardiovascular Toxicology, Vol. 21, No. 10The advantages of drug treatment with statins in patients with SARS-CoV-2 infection29 March 2021 | Wiener klinische Wochenschrift, Vol. 133, No. 17-18Antiviral effects of statinsProgress in Lipid Research, Vol. 79Pleiotropic effects of statins in the diseases of the liverWorld Journal of Gastroenterology, Vol. 22, No. 27 Vol. 8, No. 8 STAY CONNECTED Metrics History Published online 5 August 2013 Published in print August 2013 Information© Future Medicine LtdKeywordschronic hepatitis Cdirect-acting antiviralhost-targeting agentIFN-αribavirinstatintreatmentFinancial & competing interests disclosureThe authors’ research is supported by a grant from the National Natural Science Foundation of China (grant no. 81071371). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download